Average article processing time (30-45 days)
Less than 5 volumes 30 days
8 - 9 volumes 40 days
10 and more volumes 45 days
Reach us
+32 25889658
Abstract
Breakthroughs of 2015-Personalized Immunotherapy Based on Individual GWAS and Biomarkers
Biaoru Li
We at Biomarkers Journal had opportunity to report “a clue of persoanlized immunotherapy” [1]. In the late 1980s, Rosenberg and his colleagues initially administered autologous T-cells to treat malignant melanoma (such as tumor-infiltrating lymphocyte, TIL). After that, TIL, nature killer cells, cytokine-induced peripheral blood mononuclear cells (lymphokine activated killer, LAK; cytokine-induced killer cells, CIK; dendritic cells and cytokineinduced killer cells, DC-CIK), and macrophage have been greatly developed into adoptive immunotherapy. Initially, TIL had some responses to treat tumor patients, however, the cells only achieved 11-30% partial and complete responses (PR and CR) as left photo.
